

Supplementary Table 1. Comparison of Anticoagulants in the Rhythm and the Rate Control Strategy Groups according to CHA₂DS₂-VASc Score

	All (n=2508)	Rhythm control (n=1134)	Rate control (n=1374)	p value
CHA ₂ DS ₂ -VAsC 1, n (%)	n=378	n=214	n=164	
Warfarin	75 (19.8)	43 (20.1)	32 (19.5)	0.888
Dabigatran	21 (5.6)	11 (5.1)	10 (6.1)	0.687
Apixaban	22 (5.8)	13 (6.1)	9 (5.5)	0.809
Ribaroxaban	18 (4.8)	13 (6.1)	5 (3.0)	0.171
Edoxaban	4 (1.1)	3 (1.4)	1 (0.6)	0.456
CHA ₂ DS ₂ -VAsC 2, n (%)	n=531	n=261	n=270	
Warfarin	77 (14.5)	40 (14.8)	37 (14.2)	0.835
Dabigatran	107 (20.2)	60 (22.2)	47 (18.0)	0.235
Apixaban	122 (23.0)	60 (22.2)	62 (23.8)	0.675
Ribaroxaban	95 (17.9)	41 (15.2)	54 (20.7)	0.981
Edoxaban	25 (4.7)	7 (2.6)	18 (6.9)	0.113
CHA ₂ DS ₂ -VAsC 3, n (%)	n=610	n=271	n=339	
Warfarin	92 (15.1)	38 (14.0)	54 (15.9)	0.570
Dabigatran	117 (19.2)	55 (20.3)	62 (18.3)	0.537
Apixaban	116 (27.2)	83 (30.6)	83 (24.5)	0.100
Ribaroxaban	133 (21.8)	60 (22.1)	73 (21.5)	0.921
Edoxaban	29 (4.8)	13 (4.8)	16 (4.7)	0.989
CHA ₂ DS ₂ -VAsC 4, n (%)	n=375	n=132	n=243	
Warfarin	71 (18.9)	23 (17.4)	48 (19.8)	0.679
Dabigatran	64 (17.1)	24 (18.2)	40 (16.5)	0.669
Apixaban	120 (32.0)	48 (36.4)	72 (29.6)	0.203
Ribaroxaban	74 (19.7)	24 (18.2)	50 (20.6)	0.684
Edoxaban	17 (4.5)	5 (3.8)	12 (4.9)	0.796
CHA ₂ DS ₂ -VAsC 5, n (%)	n=255	n=86	n=169	
Warfarin	55 (21.6)	13 (15.1)	42 (24.9)	0.079
Dabigatran	38 (14.9)	20 (23.3)	18 (10.7)	0.013*
Apixaban	88 (34.5)	28 (32.6)	60 (35.5)	0.578
Ribaroxaban	55 (21.6)	16 (18.6)	39 (23.1)	0.530
Edoxaban	5 (2.0)	3 (3.5)	2 (1.2)	0.339
CHA ₂ DS ₂ -VAsC 6–10, n (%)	n=157	n=34	n=123	
Warfarin	38 (24.1)	11 (32.4)	27 (22.2)	0.258
Dabigatran	21 (13.4)	4 (11.8)	17 (13.8)	0.755
Apixaban	59 (37.6)	13 (38.2)	46 (37.4)	0.929
Ribaroxaban	26 (16.6)	6 (17.6)	20 (16.3)	0.847
Edoxaban	8 (5.1)	0 (0.0)	8 (6.5)	0.127

Data are presented as a number (percentage).

*Statistically significant.